Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Liabilities (2016 - 2025)

Plus Therapeutics has reported Total Liabilities over the past 16 years, most recently at $12.3 million for Q4 2025.

  • Quarterly Total Liabilities fell 20.88% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, down 20.88% year-over-year, with the annual reading at $12.3 million for FY2025, 20.88% down from the prior year.
  • Total Liabilities was $12.3 million for Q4 2025 at Plus Therapeutics, down from $13.6 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $35.7 million in Q1 2025 and troughed at $7.3 million in Q2 2025.
  • The 5-year median for Total Liabilities is $11.6 million (2022), against an average of $13.2 million.
  • The largest YoY upside for Total Liabilities was 241.34% in 2025 against a maximum downside of 61.16% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $11.1 million in 2021, then skyrocketed by 56.32% to $17.4 million in 2022, then dropped by 26.9% to $12.7 million in 2023, then increased by 22.35% to $15.6 million in 2024, then fell by 20.88% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Total Liabilities are $12.3 million (Q4 2025), $13.6 million (Q3 2025), and $7.3 million (Q2 2025).